LogicBio Therapeutics, Inc. (LOGC)

Market Cap	68.23M
Revenue (ttm)	10.16M
Net Income (ttm)	-30.95M
Shares Out	32.96M
EPS (ttm)	-1.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	152,923
Open	2.06
Previous Close	2.07
Day's Range	2.06 - 2.07
52-Week Range	0.26 - 3.53
Beta	4.62
Analysts	Buy
Price Target	2.30 (+11.1%)
Earnings Date	Nov 21, 2022

About LOGC

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials fo...

• Industry: Biotechnology
• IPO Date: Oct 19, 2018
• CEO: Frederic Chereau
• Employees: 62
• Stock Exchange: NASDAQ
• Ticker Symbol: LOGC

Financial Performance

In 2021, LOGC's revenue was $5.41 million, an increase of 56.63% compared to the previous year's $3.45 million. Losses were -$40.03 million, 22.7% more than in 2020.

Analyst Forecast

According to 10 analysts, the average rating for LOGC stock is "Buy." The 12-month stock price forecast is 2.3, which is an increase of 11.11% from the latest price.

Price Target

$2.3

(11.11% upside)

Analyst Consensus: Buy